1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
66,99,600 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Dec 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 78.32 | 60.76 | 56.28 | 38.66 |
| Total Income | 95.67 | 81.86 | 47.12 | 29.18 |
| Profit After Tax | 8.51 | 4.67 | 0.72 | -0.20 |
| NET Worth | 20.14 | 11.63 | 6.96 | 6.24 |
| Reserves and Surplus | 16.25 | 7.74 | 3.07 | 2.35 |
| Total Borrowing | 20.82 | 19.97 | 15.79 | 15.02 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹139.45 (-0.43%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹39.99 (-2.46%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (-3.09%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.50 (-1.62%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹249.60 (-0.95%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹109.90 (-0.54%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.10 (+1.15%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹67.82 (-3.02%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹551.05 (-1.70%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,042.70 (-2.23%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,466.40 (-3.39%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹167.00 (-0.86%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹14.87 (-3.06%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Upgradation / Construction of the existing premises | 4.85 |
| 2 | Funding capital expenditure requirements for the purchase of plant & machinery and furniture & fixtures | 11.42 |
| 3 | Funding capital expenditure towards establishment of new office premise with interior works and utilities | |
| 4 | To meet working capital requirements of our Company | 19.50 |
| 5 | Repayment/prepayment, in part or full, of certain of our borrowings | |
| 6 | General Corporate Purposes |
About Maxwell Life Sciences IPO
Incorporated in 2004, Maxwell Life Sciences Ltd manufactures pharmaceutical formulations for tablets, capsules, syrups, ointments, creams, liquid orals, dry syrups, and powders. Its product portfolio comprises more than 150 formulations, including Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Antacid, Anti-Ulcerants, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics, Anti-Fungal and anti-amoebic products. The company's manufacturing facility is located at Boisar, Maharashtra, across 1,510 square meters, with the capability to produce 180 crore tablets per year, 60 crore capsules per year, 1.80 crores bottles of syrup per year and 1.80 crores tubes of ointment per year. Its manufacturing process is approved by the World Health organization (WHO) for Good Manufacturing Practices (GMP) and Good Laboratory process (GLP) certification issued by Food & Drugs Administration, Maharashtra. The company supplies pharmaceutical formulations to private companies, merchant exporters, and the government contracts. Under contract manufacturing, it produces pharmaceutical formulations for private companies or parties, which then market and distr
Contact Details
Maxwell Life Sciences AddressOffice No. 5,Target Mall Chandrvarker Road,Borivali West, MumbaiMumbai, Maharashtra, 400092+91-022-45227279compliance@mlspl.inVisit Website